For someone living with a mental health condition, considering a clinical trial can bring hope, questions, and uncertainty alongside the challenges they already face. Thoughtful patient recruitment begins with listening – understanding patient experiences, respecting their concerns, and helping them make an informed choice.
The theme associated with Mental Health Awareness Month, “Lived experiences heard: real voices, real change,” calls for those voices to shape policies and decisions that affect their lives. To mark October’s focus on mental health awareness, we are exploring a recent Clariness Major Depressive Disorder (MDD) survey and how patient insights inform a recruitment approach grounded in people’s needs.
Clariness surveyed 1,044 people aged 18-74 across Argentina, Poland, Germany, and the United States who all reported having a doctor’s diagnosis of depression, to understand the lived realities of MDD. Their responses offer insight into the realities of people with a mental health condition and what patient recruitment must accommodate.
The daily burden of living with depression
85% of respondents reported five or more symptoms experienced almost every day during the previous two weeks. The significance lies in both their frequency and their number: People described several difficulties occurring within the same period, repeatedly.
In the last two weeks, which of the following symptoms have you experienced almost everyday?
When daily life requires more energy than someone has: “Feeling very tired” was the most frequently reported symptom, selected by 89% of respondents. Alongside this, 75% reported that “thinking or making decisions was harder than usual”.
Together, these findings suggest a burden that reaches into the ordinary demands of daily life. Preparing a meal, responding to a message, keeping an appointment, or deciding what to do next may require considerable effort when energy and concentration are limited.
Symptoms noted also include changes in sleep and appetite. These responses add to a picture of depression experienced across emotional, cognitive, and physical aspects of life. A single symptom label cannot fully convey what managing several of these difficulties day after day means.
Losing enjoyment while carrying sadness and guilt: 82% reported no longer enjoying things they usually liked, and the same proportion reported feeling very sad. 75% also noted “feeling worthless or very guilty”.
Loss of enjoyment can mean that activities or time with others no longer offer the pleasure someone once found in them. Feelings of guilt or worthlessness may add further emotional weight to difficulties with everyday tasks. The responses invite us to consider both what people are struggling to do and how they may feel about those struggles.
For many, these difficulties were part of a recurring experience. At the time of the survey, 81% reported a current depressive episode (a period of depression that persists for at least two weeks). Among them, 74% reported at least three previous episodes. Meanwhile, 67% said their MDD diagnosis dated back more than three years.
For many respondents, the survey therefore captured a difficult period within a much longer history of living with depression.
Treatment experiences provide additional context: Only 60% of diagnosed patients were taking MDD medication, with no knowledge of specific antidepressant medications, such as SSRIs, SNRIs, tricyclics, TCAs, MAOIs, or NDRIs, and were unsure if they were taking them. Among respondents taking medication, 44% were dissatisfied with their current treatment, revealing crucial unmet treatment needs.
A recruitment invitation arrives within these daily realities. Reading study information, recalling medication history, or completing a screening questionnaire may require energy and concentration that someone is already struggling to find.
Mental health clinical trials: The awareness gaps
For people managing these experiences, considering a clinical trial introduces another set of questions and decisions. 82% of respondents had never explored or participated in an MDD clinical trial, and just 3% reported previous participation.
Have you ever looked into clinical studies for MDD?
When asked whether they would be interested in a trial testing a new drug for MDD, 39% said “yes”, while an equally large proportion said “no”. The remaining respondents were “unsure”.
Would you be interested in participating in a clinical trial to test a new drug for treating MDD?
These findings show that trial participation cannot be assumed to follow from a diagnosis or dissatisfaction with treatment. Someone may want their situation to improve while still having research concerns, preferring established care, or feeling unable to take on further commitments.
The motivations and barriers reported in this MDD survey help explain what people may be weighing.
What motivates patient participation in mental health clinical trials?
That distinction deserves attention. It suggests that, for this surveyed group, the medical support surrounding participation was an important part of its appeal. The prospect of monitoring and contact with a study team may matter alongside interest in the treatment itself. These responses do not establish dissatisfaction with existing clinical care, but they underline the value respondents placed on support.
Motivators to participation in an MDD clinical trial
Financial considerations also featured: 36% selected reimbursement for participation, and 31% selected reimbursement for travel expenses. These findings suggest that the practical affordability of participation belongs within the conversation about access.
Meanwhile, 33% identified contributing to medical knowledge as a motivation.
Personal health needs and a wish to help research can coexist. Understanding participation therefore requires room for different motivations, rather than assuming everyone is looking for the same outcome.
What barriers limit patient participation in mental health clinical trials?
Fear of side effects was reported by 55%, while travel costs were a barrier for 53%, showing practical expense featured almost as often as concern about the treatment’s effects.
Barriers to participation in an MDD clinical trial
For someone already navigating persistent symptoms or uncertainty about treatment, concerns about side effects may add another worry. Interest in a new treatment does not remove the need to weigh that uncertainty carefully.
Travel costs present a different challenge. Even when a person wants to participate, repeated journeys may be financially difficult. Time commitment, identified by 35%, adds another demand. Appointments involve the time spent travelling and organizing the day as well as the visit itself.
Limited awareness of clinical trials was also reported as a barrier by 42%. This reinforces the earlier finding that most respondents have never explored an MDD trial. Before assessing a particular study, some may first need to understand how research works and what joining could mean for their care.
Taken together, these barriers show why a potentially appealing trial opportunity can still feel difficult to pursue. Medical support may encourage consideration, while concerns about side effects, cost, and time remain unresolved.
What does this mean for MDD patient recruitment?
Across the responses, two connected realities emerge: many respondents were managing frequent, overlapping symptoms, and most had little familiarity with MDD clinical research. Considering a clinical trial, asks people to process new information and make decisions while already carrying that burden.
For sponsors, this has three practical takeaways:
- Reduce the effort required to explore a study: Short, clearly structured information, straightforward screening questions, and help with treatment terminology can make initial steps more manageable for someone experiencing fatigue or difficulty concentrating.
- Explain the support as clearly as the study: Describe what medical monitoring involves, who can answer questions, and what remains uncertain about the investigational treatment. Give people time to consider the information and respect the decision not to participate.
- Address the practical demands early: Make visit schedules, travel requirements, and reimbursement arrangements clear from the outset. Where possible, use patient insights to inform arrangements that reduce the burden of attending.
At Clariness, patient understanding directly shapes how we communicate studies as part of our patient recruitment and retention strategies. Knowing the experiences behind the responses helps identify where clearer information, personal support, or fewer avoidable demands make a real difference.
This is where listening can lead to change: in a recruitment experience that takes people’s difficulties seriously and helps them decide whether participation fits their lives.